ABSTRACT
Newcastle disease is highly infectious viral disease causing huge economic losses worldwide. These losses can be prevented by control of viral diseases. Medicinal plants have been traditionally used for treatment of different diseases since long. In this study the effect of extracts from Glycyrrhiza glabra leaves are investigated against Newcastle disease virus [NDV] by an in-vivo assay. Seven groups of nine-day-old embryonated chicken eggs were inoculated with various treatments of different plant extracts. All the groups except uninoculated negative control group were inoculated with velogenic NDV strain; five groups received different concentrations of the three extracts. Daily observe the rate of embryo survival. Allantoic fluid from treated eggs was collected for hem agglutination test. Results showed that embryo survival rate was higher 300micro g/mL treated group as all the extracts showed antiviral activity. Similarly, the plant extracts effectively control virus as no viruses were identified in the allantoic fluids of all groups treated with low doses of plant. The current results have clearly verified that all the extracts especially that of methanol 300micro g/mL from leaves of Glycyrrhiza glabra have strong antiviral activity against NDV in vivo
ABSTRACT
Diabetes is a metabolic disorder characterized by chronic hyperglycemia and associated with dysfunction and failure of various body organs. Alarming increase in prevalence rate has made this disorder a major health problem globally. The available treatment modalities are not sufficient to combat diabetes and associated complications. A number of medicinal plants have a significant antidiabetic potential against diabetes mellitus. We have listed the use of important medicinal herbs for the treatment and management of diabetes in this review
ABSTRACT
Glimepiride and Atorvastatin in combination are commonly employed for treating the hyperglycemia and dyslipidemia, respectively, in patients of type 2 diabetes. The present study was designed to find out the influence of Atorvastatin on urinary excretion and renal clearance of Glimepiride in healthy adult male volunteers. In each experimental subject, Glimepiride 2mg was given orally after an overnight fasting. Samples of blood and urine were taken at different specific time intervals. After a washout period of ten days, Glimepiride 2mg was co-administered with Atorvastatin 20mg orally. Post-medication, blood and urine samples were collected following the same sampling schedule as for Glimepiride alone. The samples were analyzed for Glimepiride and creatinine concentration by HPLCUV and Spectrophotometer, respectively. Mean [ +/- SE] values for blood pH 7.445 +/- 0.05 and 7.382 +/- 0.05, urine pH 4.972 +/- 0.08 and 5.08 +/- 0.10, diuresis 0.0207 +/- 0.00 and 0.0237 +/- 0.00ml/min/kg, endogenous creatinine in plasma 9.048 +/- 0.33 and 8.613 +/- 0.024 micro g/ml, endogenous creatinine in urine 512.34 +/- 18.20 and 556.72 +/- 4.60 micro g/ml, Glimepiride plasma concentration 0.16069 +/- 0.00 and 0.3227 +/- 0.01 micro g/ml, Glimepiride urine concentration 1.5994 +/- 0.03 and 0.8665 +/- 0.04 micro g/ml, renal clearance of creatinine 1.224 +/- 0.09 and 1.550 +/- 0.09ml/min/kg, renal clearance of Glimepiride 0.2064 +/- 0.01 and 0.0641 +/- 0.00ml/min/kg and clearance ratio 0.1791 +/- 0.01 and 0.0414 +/- 0.00 were observed for Glimepiride alone and its concurrent administration with Atorvastatin, respectively. Atorvastatin decreased the urinary excretion and renal clearance of Glimepiride due to which chances of hypoglycemia provokes and renal handling of Glimepiride involves back diffusion besides glomerular filtration and no influence of Atorvastatin was seen on these mechanisms
ABSTRACT
Cefixime is a third generation and orally acting cephalosporin. It is a cell wall synthesis inhibitor and is well stable to presence of beta lactamase enzymes. Environmental and genetic differences play a greater role in disposition kinetics of a drug. To determine disposition kinetics of cefixime in local population and to evaluate the bioequivalence of multinational and national brands of cefixime. 2013-2014. Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad. In present study disposition kinetics and bioequivalence of two brands of cefixime, cefspan and ceforal-3, were investigated in 10 adult healthy male subjects after a single oral dose of 400 mg capsule of each with a 7 days washout period. After blood sampling, plasma concentration of cefixime was determined by HPLC method. For computing disposition kinetic parameters, one compartment open model was applied. Mean values of disposition kinetic parameters; t1/2 Beta 5.01 and 4.72 hours, Vd 1.10 and 1.29 L/kg and CI[B] 0.16 and 0.21 L/hr/kg of cefspan and ceforal-3, respectively, were found non significantly [P 0.05] different. Similarly mean values of bioavailability parameters; AUC 36.58 and 32.99microg.hr/mL, AUMC 282.95 and 264.13 microL/g.hr[2]/mL and MRT 7.79 and 7.83 hours of cefspan and ceforal-3, respectively, remained non significantly [P > 0.05] different. All the parameters were compared by paired t-test. Relative bioavailability was found to be within the range 80-125% which is acceptable for bioequivalence. The test formulation, ceforal-3, was found bioequivalent to the reference formulation, cefspan